Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Chimerix Inc (CMRX)

Chimerix Inc (CMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 98,131
  • Shares Outstanding, K 89,210
  • Annual Sales, $ 320 K
  • Annual Income, $ -82,100 K
  • 60-Month Beta 1.16
  • Price/Sales 316.64
  • Price/Cash Flow N/A
  • Price/Book 0.52
Trade CMRX with:

Options Overview Details

View History
  • Implied Volatility 49.41% ( +7.68%)
  • Historical Volatility 61.73%
  • IV Percentile 37%
  • IV Rank 13.66%
  • IV High 354.84% on 02/23/24
  • IV Low 1.08% on 09/27/23
  • Put/Call Vol Ratio 0.40
  • Today's Volume 35
  • Volume Avg (30-Day) 54
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 3,087
  • Open Int (30-Day) 3,096

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.21
  • Number of Estimates 3
  • High Estimate -0.20
  • Low Estimate -0.21
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1000 unch
on 03/18/24
1.3000 -15.38%
on 03/08/24
-0.0500 (-4.35%)
since 02/16/24
3-Month
0.8830 +24.58%
on 02/05/24
1.3000 -15.38%
on 03/08/24
+0.1499 (+15.78%)
since 12/18/23
52-Week
0.8800 +25.00%
on 11/10/23
1.5700 -29.94%
on 06/07/23
-0.1800 (-14.06%)
since 03/17/23

Most Recent Stories

More News
Chimerix: Q4 Earnings Snapshot

Chimerix: Q4 Earnings Snapshot

CMRX : 1.1000 (-4.35%)
Chimerix: Q3 Earnings Snapshot

Chimerix: Q3 Earnings Snapshot

CMRX : 1.1000 (-4.35%)
Chimerix: Q2 Earnings Snapshot

Chimerix: Q2 Earnings Snapshot

CMRX : 1.1000 (-4.35%)
Chimerix (CMRX) Reports Q1 Loss, Misses Revenue Estimates

Chimerix (CMRX) delivered earnings and revenue surprises of 0% and 19.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CMRX : 1.1000 (-4.35%)
EGRX : 5.62 (-7.11%)
Chimerix: Q1 Earnings Snapshot

Chimerix: Q1 Earnings Snapshot

CMRX : 1.1000 (-4.35%)
Chimerix (CMRX) Loses -24.68% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Chimerix (CMRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings...

CMRX : 1.1000 (-4.35%)
Chimerix: Q4 Earnings Snapshot

Chimerix: Q4 Earnings Snapshot

CMRX : 1.1000 (-4.35%)
Green Thumb Industries Inc. (GTBIF) Q4 Earnings Lag Estimates

Green Thumb Industries Inc. (GTBIF) delivered earnings and revenue surprises of -28.57% and 1.78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

GTBIF : 13.5200 (+4.97%)
CMRX : 1.1000 (-4.35%)
Chimerix (CMRX) Upgraded to Buy: What Does It Mean for the Stock?

Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CMRX : 1.1000 (-4.35%)
Rubric Capital Management Sends Letter to Chimerix Board of Directors

Rubric Capital Management LP (“Rubric”), an investment adviser whose managed funds and accounts collectively own approximately 8.5% of the common stock of Chimerix, Inc. (“Chimerix” or the “Company”)...

CMRX : 1.1000 (-4.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical...

See More

Key Turning Points

3rd Resistance Point 1.2167
2nd Resistance Point 1.1933
1st Resistance Point 1.1467
Last Price 1.1000
1st Support Level 1.0767
2nd Support Level 1.0533
3rd Support Level 1.0067

See More

52-Week High 1.5700
Fibonacci 61.8% 1.3064
Fibonacci 50% 1.2250
Fibonacci 38.2% 1.1436
Last Price 1.1000
52-Week Low 0.8800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar